Transplantations using umbilicoplacental blood cells internationally tend to replace those of bone marrow and peripheral blood, as results are better. In 2007 the first large study establishes the use of umbilicoplacental blood stem cells as the first treatment approach whether or not there is an histocompatible bone marrow donor. The results of 613 pediatric patients (<16 years old) with acute leukemia, were announced in the 5th Annual International Conference on Transplantations of Umbilicoplacental Blood which took place in 2007, in Los Angeles USA.
Mary Ňapen M.D. Center for International Blood and Marrow Transplant Research. 2007 May 11-12 Los Angeles CA USA.

To date in Europe 25,000 transplantations have been performed using hemopoietic stem cells (bone marrow, peripheral blood and umbilicoplacental blood). 70% of these transplantations were autologous, namely the stem cells came from the patient and 30% were heterologous, namely the stem cells came from a donor, of which 70% came from a donor member of the family.
Watt et al 2007, Methods Mol Biol 368: 237-25

To date, stem cells of umbilicoplacental blood have been used in the treatment of more than 40 diseases related to malignancies, birth defects, immunodeficiencies and hematological disorders.

 
Malignancies
 
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
  • Chronic Myeloid Leukaemia
  • Juvenile Chronic Myeloid Leukaemia
  • Juvenile Myelomonocytic Leukemia Acute Biphenotypid Leukemia
  • Acute Undifferentiated Leukemia
  • Myelodysplastic syndrome
  • Neuroblastoma
  • Burkitt Lymphoma
  • Non- Hodgkin Lymphoma 
 
Immunodeficiencies
 
  • Adenosine deaminase deficiency
  • Severe mixed immunodeficiency
  • X-linked lymphoproliferative disease
  • Wiskott - Aldrich syndrom
 
Hereditary metabolic diseases
 
  • Adenoleukodystrophy
  • Bare lymphocyte syndrome
  • Congenital dyskeratosis
  • Familial erythrophagocytic lymphohistiocytosis
  • Gaucher's disease
  • Gunter's disease
  • Hunter's disease
  • Hurler syndrome (genetic)
  • Hereditary neuronal ceroid lipofuscinosis
  • Krabbe Disease
  • Langerhans cell histocytosis
  • Lesch – Nyhan Disease
  • Leukocyte-adhesion deficiency
 
Hemoglobinopathies – Blood Disorders
 
  • Amegakaryocytic thrombocytopenia
  • Aplastic anemia
  • Blackfan – Diamond anemia
  • Familial cytopenia
  • Evans syndrome
  • Fanconi anemia (genetic)
  • Kost mann syndrome (genetic)
  • Sickle cell anemia
  • Thalassemia

At the same time, internationally intensified are experimental approaches and clinical trials with umbilicoplacental blood stem cells to investigate their qualities and to extend their application in the treatment of diseases such as:

Cardiovascular diseases

  • Autoimmune diseases
    • Type-1 diabetes
    • Systemic lupus erythematosus
    • Rheumatoid arthritis
    • Multiple sclerosis
  • Alzheimer's disease
  • Parkinson's disease
  • Malignant tumors
  • Strokes.

The use of stem cells does not guarantee cure. Stem cell application possibilities are relatively limited.